Purpose: To identify long peptides (LP) derived from a novel tumor-associated antigen (TAA), kinesin family member 20A (KIF20A), which induce tumor-specific T-helper type 1 (TH1) cells and CTLs.

Experimental Design: We combined information from a recently developed computer algorithm predicting HLA class II–binding peptides with KIF20A-derived CTL-epitope sequences presented by HLA-A2 (A*02:01) or HLA-A24 (A*24:02) to select candidate promiscuous TH1-cell epitopes containing CTL epitopes. Peripheral blood mononuclear cells (PBMC) derived from healthy donors or patients with head-and-neck malignant tumor (HNMT) were used to study the immunogenicity of KIF20A-LPs, and the in vitro cross-priming potential of KIF20A-LPs bearing CTL epitopes. We used HLA-A24 transgenic mice to address whether vaccination with KIF20A-LP induces efficient cross-priming of CTLs in vivo. The TH1-cell response to KIF20A-LPs in HNMT patients receiving immunotherapy with TAA-derived CTL-epitope peptides was analyzed using IFN-γ enzyme-linked immunospot assays.

Results: We identified promiscuous KIF20A-LPs bearing naturally processed epitopes recognized by CD4+ T cells and CTLs. KIF20A-specific CTLs were induced by vaccination with a KIF20A-LP in vivo. KIF20A expression was detected in 55% of HNMT by immunohistochemistry, and significant frequencies of KIF20A-specific TH1 cell responses were detected after short-term in vitro stimulation of PBMCs with KIF20A-LPs in 50% of HNMT patients, but not in healthy donors. Furthermore, these responses were associated with KIF20A expression in HNMT tissues.

Conclusions: These are the first results showing the presence of KIF20A-specific TH1 cell responses in HNMT patients and underline the possible utility of KIF20A-LPs for propagation of TH1 cells and CTLs. Clin Cancer Res; 19(16); 4508–20. ©2013 AACR.

See related commentary by Melief, p. 4295

Translational Relevance

We recently identified a novel tumor-associated antigen, kinesin family member 20A (KIF20A), overexpressed in various malignancies. Phase I/II clinical trials of immunotherapy for several cancers using a KIF20A-derived CTL epitope are underway. We identified promiscuous KIF20A LPs bearing naturally processed epitopes recognized by CD4+ T cells and CTLs. KIF20A-LPs stimulated KIF20A-specific CTLs in vitro and in vivo. In addition, KIF20A-LP and a T-helper type 1 (TH1) cell clone enhanced induction of KIF20A-specific CTLs in vitro. Thus, KIF20A-LPs provide a useful tool for propagation of both TH1 cells and CTLs. This report also describes the first immunohistochemical detection of KIF20A expression in cases of head-and-neck malignant tumor (HNMT), and the first detection of KIF20A-LPs–specific TH1 cell responses in patients with HNMT. These findings will support clinical trials of KIF20A peptide–based immunotherapy for various cancers.

We recently used genome-wide cDNA microarray analysis to identify a novel tumor-associated antigen (TAA), kinesin family member 20A (KIF20A), which is frequently overexpressed in lung cancer, pancreatic cancer, gastric cancer, bladder cancer, breast cancer, melanoma, and various other malignancies (1–3). KIF20A has been reported to be a promising immunotherapeutic target for cancers. Studies have reported that 2 short peptides (SP) derived from KIF20A, KIF20A-A2809–917, and KIF20A-A2466–75 stimulated CTLs, which kill cancer cells endogenously expressing KIF20A antigen and that KIF20A-specific CTLs were present in peripheral blood mononuclear cells (PBMC) obtained from patients with pancreatic cancer (1, 4). Phase I/II clinical trials of cancer immunotherapy for lung cancer, pancreatic cancer, and cholangiocellular carcinoma using KIF20A-derived SP are underway. In these trials, we observed that vaccination with a KIF20A-derived SP induced a KIF20A-specific CTL response and yielded promising results in patients with advanced cancer (manuscript in preparation). Therefore, we propose that KIF20A is an attractive target molecule for cancer immunotherapy. We have attempted to identify LP that induce both antigen-specific CD4+ helper T (TH) cells and CTLs to further develop peptide vaccine immunotherapy.

Tumor-specific TH cells, particularly T-helper type 1 (TH1) cells, play a critical role in efficient induction of CTL-mediated antitumor immunity (5). IFN-γ produced by TH1 cells is critical for induction and maintenance of long-lived CTL responses through multiple interactions (6, 7). IFN-γ secreted by TH1 cells also mediates direct antitumor or antiangiogenic effects (8). Furthermore, TH cells pave the way for entry of CTLs at the tumor site (9). Therefore, identification of TH-cell epitopes that can activate tumor-specific TH1 cells is important for induction of effective tumor immunity in tumor-bearing hosts.

Melief and colleagues recently reported a synthetic LP naturally bearing a CTL epitope as an attractive vaccine compound. Following injection of LP, a patient's dendritic cells take up the LP, process it, and present all possible CTL epitopes and TH-cell epitopes in the context of various HLA class I and class II molecules (10). In addition, recent clinical studies using a promiscuous telomerase–derived helper-epitope vaccine called GV1001 bearing CTL epitopes, increased survival of cancer patients when combined with radiotherapy and chemotherapy (11, 12). Thus, we proposed that an ideal peptide vaccine for cancer immunotherapy may be a single polypeptide containing epitopes for both TH1 cells and CTLs, which are naturally proximal to each other and can be induced simultaneously (10, 13).

In this study, a recently developed computer algorithm predicting HLA class II–binding peptides and known CTL-epitope sequences recognized by HLA-A2 or HLA-A24–restricted CTLs were used to select candidate promiscuous TH-cell epitopes containing the CTL epitopes. Our results show that the predicted LPs triggered TH1 responses in individuals expressing several common HLA-DR or HLA-DP alleles, and that the KIF20A-LPs bearing CTL epitopes efficiently stimulated KIF20A-specific CTLs.

Patients

Blood samples were collected from 16 patients with a head-and-neck malignant tumor (HNMT). The immune responses of TH cells reactive to KIF20A-LPs were investigated. The patients were receiving immunotherapy with TAA-derived CTL-epitope peptides, and were enrolled in 2 peptide vaccine trials. These phase I/II clinical trials of cancer immunotherapy using 3 HLA-A24-binding SPs (clinical-grade 9-10-amino acid-SPs) derived from 3 cancer-testis antigens, LY6K (LY6K-A24177–186), IMP-3 (IMP-3-A24508–516), and CDCA1 (CDCA1-A2456–64) were reviewed and approved by the Institutional Review Board of Kumamoto University (Kumamoto, Japan; ref. 14–16). This vaccine cocktail did not include KIF20A-derived SPs. All patients with HNMT were selected on the basis of HLA-A24 presence after providing written informed consent. The patients suffered from inoperable advanced HNMT with recurrent or metastatic tumors and were resistant to standard therapy; they were enrolled in the trial under University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number 000008379 (CTR-8379). The patients with radical resection were enrolled in the trial under UMIN-CTR number 000008380 (CTR-8380). In the latter trial, patients were treated with postoperative peptide vaccine combined with S-1, ifosfamide, or doxorubicin. These clinical trials and analyses are ongoing.

Cell lines

Mouse fibroblast cell lines (L-cells), genetically engineered to express DR4 (DRB1*04:05), L-DR4; DR8 (DRB1*08:03), L-DR8; DR15 (DRB1*15:02), L-DR15; or DR53 (DRB4*01:03), L-DR53 were used as antigen-presenting cells (APC). The HLA-A24-positive C1R-A2402 cells were a gift from Dr. M. Takiguchi (Kumamoto University; ref. 17).

Prediction of HLA class II–binding peptides

To predict possible promiscuous HLA class II–binding human KIF20A-derived peptides, the amino acid sequence of the human KIF20A protein was analyzed by a recently developed computer algorithm (IEDB analysis resource, consensus method, http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html; refs. 18 and 19). The program analyzed 15-amino acid-long sequences offset to encompass the entire protein. The 24- and 25-amino acid-LPs with overlapping high consensus percentile ranks for multiple HLA class II molecules encoded by DRB1*04:05, DRB1*15:02, or DRB4*01:03 alleles, KIF20A60–84-LP (DSMEKVKVYLRVRPLLPSELERQED), KIF20A494–517-LP (TLHVAKFSAIASQLVHAPPMQLGF), and KIF20A809–833-LP (CIAEQYHTVLKLQGQVSAKKRLGTN), were selected (Supplementary Fig. S1 and Table S1).

Synthetic peptides and recombinant proteins

Human KIF20A-derived SPs presented by HLA-A2 (KIF20A-A2809–817) or HLA-A24 (KIF20A-A2466–75), and 3 LPs (KIF20A60–84-LP, KIF20A494–517-LP, and KIF20A809–833-LP) were synthesized (MBL, Nagoya, Japan; purity >95%; Supplementary Fig. S1B). A human immunodeficiency virus (HIV) peptide that binds to HLA-A24 (HIV-A24) was used as a negative control SP (17). A WT1-derived LP presented by HLA-DR4 (WT1-peptide) and a promiscuous HIV-derived LP were used as negative control LPs (20, 21). Peptides were dissolved in dimethylsulfoxide at 10 μg/μL. The recombinant whole KIF20A and CDCA1 protein were expressed by Escherichia coli BL21 with a pET28a vector (Novagen). The CDCA1 protein was used as a control. Each recombinant protein was purified and assessed by SDS-PAGE.

Generation of antigen-specific CD4+ T cells from healthy donors

The research protocol for collecting and using PBMCs from healthy donors (HD1–HD11; Supplementary Table S2) was approved by the Institutional Review Board of Kumamoto University. We obtained PBMCs from 11 healthy donors with written informed consent. Genotyping of HLA-A, DRB1, and DPB1 was conducted at the HLA Laboratory (Kyoto, Japan; Supplementary Table S2). With some modifications, induction of antigen-specific CD4+ T cells was conducted as described previously (22). Detailed methods are provided in Supplementary Materials and Methods. In some instances, T cells were cloned by limiting dilution for further studies as described previously (23).

Assessment of T-cell responses to peptides and proteins

The immune response of TH cells to APCs pulsed with peptides (10 μg/mL) or proteins (50 μg/mL) was assessed by IFN-γ enzyme-linked immunospot (ELISPOT) assays (BD Biosciences) as described previously (17). In brief, the frequency of peptide-specific CD4+ T cells producing IFN-γ per 3 × 104 bulk CD4+ T cells in response to stimulation with peptide-pulsed PBMCs (3 × 104 cells/well), or 1 × 104 bulk CD4+ T cells in response to stimulation with peptide-pulsed L-cells expressing HLA-DR (5 × 104 cells/well) was analyzed. The frequency of KIF20A-LP–specific TH-cell clone (TH clone) producing IFN-γ per 2 × 104 TH clone in response to stimulation with protein-loaded dendritic cells (5 × 103 cells/well) was analyzed. To determine the HLA molecules involved in antigen presentation, antigen-induced IFN-γ production was blocked by adding anti-HLA-DR monoclonal antibody (mAb; L243, BioLegend), anti-HLA-DP mAb (B7/21, Abcam), anti-human HLA-DQ mAb (SPV-L3, Abcam), or anti-HLA class I mAb (W6/32, Abcam; refs. 24–26). All mAbs were used at a final concentration of 5 μg/mL. All assessments of IFN-γ ELISPOT assays were conducted in triplicate or duplicate, and results are presented as means ± SD.

Immunohistochemical examination

Immunohistochemical staining of KIF20A using a rabbit polyclonal antibody against KIF20A (A300-879A, Bethyl Laboratories) was conducted as described previously (1, 2, 27).

Cytokine assays and CD107a mobilization assay

HLA-DP2–restricted KIF20A60–84-LP–specific bulk TH cells (3 × 104 cells/well) were cultured with autologous PBMCs (3 × 104 cells/well) in the presence of cognate peptide in 96-well culture plates. HLA-DR53–restricted KIF20A809–833-LP–specific bulk TH cells were cultured with L-DR53 (5 × 104 cells/well) in the presence of cognate peptide. After 24 hours, culture supernatants were collected and cytokine [TNF-α, IFN-γ, granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein (MIP)1β, interleukin (IL)-2, IL-4, and IL-7] levels were measured using the Bio-Plex system (Bio-Rad) according to manufacturer's instructions.

Peptide-stimulated degranulation of CD4+ T lymphocytes was determined by flow cytometric analysis of CD107a exposed on the cell surface as described previously, with some modifications (28). Detailed methods are provided in Supplementary Materials and Methods.

The synergistic effect of KIF20A-LPs on induction of KIF20A-specific CTLs

PBMCs obtained from an HLA-A2+/DR53+/DP2+ donor (HD2), from whom the KIF20A60–84-LP or KIF20A809–833-LP–specific TH clones were generated, were plated in 24-well plates (3 × 106 cells/well), followed by addition of SP alone (KIF20A-A2809–817 SP, 20 μg/mL), or SP + LP (KIF20A60–84-LP or KIF20A809–833-LP, 20 μg/mL), or SP + LP + Th-clone (5 × 105 cells/well) in a final volume of 2 mL. After culture for 7 days, these peptides and IL-2 (20 U/mL) were added, then IL-15 (5 ng/mL) was added on day 9. On day 11, cells were stained with phycoerythrin-labeled tetramer of the HLA-A*02:01/KIF20A-A2809–817-complex and a fluorescein isothiocyanate–labeled anti-human CD8 mAb. Data acquisition was conducted on a FACSCalibur (BD Biosciences), and data files were analyzed with FlowJo software (Tree Star).

In vitro stimulation of KIF20A-A2809–817 SP-specific CTLs with KIF20A809–833-LP

Induction of KIF20A-A2809–817 SP-reactive bulk CTLs from an HLA-A2+ and DR53+ donor (HD5) by stimulation with KIF20A-A2809–817 SP was conducted as described (28, 29). In brief, purified human CD8+ T cells were stimulated with KIF20A-A2809–817 SP-pulsed dendritic cells. After 3 rounds of stimulation, we confirmed that CTLs specifically produced IFN-γ in response to restimulation with T2 cells pulsed with KIF20A-A2809–817 SP; thus, the KIF20A-A2809–817 SP–reactive CTLs were used as effector cells.

To prove the stimulation of KIF20A-A2809–817 SP–reactive CTLs with KIF20A809–833-LP–loaded dendritic cells, the number of IFN-γ producing KIF20A-A2809–817 SP–specific bulk CTLs in response to stimulation with the KIF20A809–833-LP–loaded autologous dendritic cells was counted by an ELISPOT assay. The LP-loaded mature dendritic cells were prepared from positively isolated CD14+ cells (day 0). CD14+ cells were cultured in the presence of IL-4 (10 ng/mL) and GM-CSF (100 ng/mL). KIF20A809–833-LP (50 μg/mL) and OK432 were added on day 5. The LP-loaded mature dendritic cells were harvested on day 7, washed, and used as APCs in an ELISPOT assay.

Assessment of KIF20A-LPs–specific CD4+ T-cell responses in patients with HNMT

Fresh PBMCs from patients with HNMT or healthy donors were cultured with a mixture of KIF20A60–84-LP and KIF20A809–833-LP (10 μg/mL each) in a final volume of 2 mL AIM-V supplemented with 5% human decomplemented plasma at 37°C (2 × 106 cells/well, 24-well plates); both recombinant human (rh) IL-2 and rhIL-7 were added on day 0 and 2. After 1 week of cell culture, the PBMCs were collected, washed, and cultured in ELISPOT plates (1 × 105 cells/well) with KIF20A60–84-LP, KIF20A809–833-LP, or control LP for 18 hours. The number of KIF20A-LP–specific TH cells expressed as spot-forming cells/105 cells was calculated after subtracting control values (background). Responses were scored as positive when the mean number of IFN-γ spots was more than 15 and more than twofold over background. The ELISPOT assays on patients' cells were conducted in single, duplicate, or triplicate wells because of the limited number of available cells. This study was conducted in a laboratory that operates under exploratory research principles, and was conducted using investigative protocols. We acknowledge the recommendations of the Minimal Information About T-cell Assays reporting framework for human T-cell assays (30).

Statistical analysis

Data were compared by the two-tailed Student t test (bar graphs), or by the nonparametric Mann–Whitney U test (scatter-dot graph). Differences with a P value < 0.05 were considered statistically significant for all tests.

Prediction and selection of possible promiscuous HLA class II–binding KIF20A-LPs

To identify possible promiscuous HLA class II–binding TH-cell epitopes of KIF20A, we first examined the amino acid sequence of KIF20A using a recently developed computer algorithm (Supplementary Fig. S1A; refs. 18 and 19). Two LPs, KIF20A60–84-LP and KIF20A809–833-LP, predicted by the computer algorithm to be potent promiscuous HLA class II–binding peptides, were identified proximal to known 9- or 10-mer CTL epitopes recognized by HLA-A2- or A24-restricted CTLs (Supplementary Fig. S1B and Table S1). Another peptide, KIF20A494–517-LP, was also predicted to be a potent promiscuous HLA class II–binding peptide, although it did not include a known CTL-epitope sequence. Therefore, 3 candidate LPs, KIF20A60–84-LP, KIF20A494–517-LP, and KIF20A809–833-LP, predicted to have strong binding affinity to HLA class II molecules HLA-DR4, HLA-DR15, or HLA-DR53 were synthesized for subsequent analyses.

Identification of promiscuous KIF20A-derived TH-cell epitopes

CD4+ T cells isolated from PBMCs of healthy donors were stimulated at weekly intervals with autologous dendritic cells or PBMCs pulsed with KIF20A60–84-LP as described in the Materials and Methods section. After at least 3 rounds of stimulation, KIF20A60–84-LP–specific responses of CD4+ T cells were examined by IFN-γ ELISPOT assays. In an HLA-DR15+ HD1, the generated TH cells produced a significant amount of IFN-γ in response to KIF20A60–84-LP–pulsed PBMCs in an HLA-DR–dependent manner. The bulk TH cells specifically recognized L-DR15 cells pulsed with KIF20A60–84-LP in an HLA-DR–dependent manner, but not KIF20A60–84-LP–pulsed L-DR8 cells (Fig. 1A). These results indicated that KIF20A60–84-LP was presented by HLA-DR15.

Figure 1.

Induction of KIF20A-specific TH cells from healthy donors. A, KIF20A-specific TH cells were generated from a DR15+ healthy donor (HD1) by stimulation of purified CD4+ T cells with KIF20A60–84-LP. The generated TH cells were restimulated with autologous PBMCs or L cells pulsed with KIF20A60–84-LP. The number of IFN-γ–producing TH cells was analyzed by ELISPOT assay. Data are presented as the mean ± SD of triplicate assays. Representative data from at least 3 independent experiments with similar results obtained from HD1 are shown. The HLA class II genotype of HD1 is indicated above the panels. The underlined HLA class II alleles encode the HLA class II molecule presenting the peptides to TH cells. B, HLA-DP2–restricted KIF20A60–84-LP–specific bulk TH cells (left) or a TH clone (right) derived from HD2 was established. An HLA-DP–restricted TH clone was cocultured with allogeneic PBMCs derived from HLA-DP2-positive or HLA-DP2-negative donors pulsed/unpulsed with KIF20A60–84-LP. C, KIF20A809–833-LP–specific HLA-DR15–restricted TH cells were generated from a healthy donor (HD1). D, KIF20A809–833-LP–specific HLA-DR53–restricted TH cells were generated from a healthy donor (HD2).

Figure 1.

Induction of KIF20A-specific TH cells from healthy donors. A, KIF20A-specific TH cells were generated from a DR15+ healthy donor (HD1) by stimulation of purified CD4+ T cells with KIF20A60–84-LP. The generated TH cells were restimulated with autologous PBMCs or L cells pulsed with KIF20A60–84-LP. The number of IFN-γ–producing TH cells was analyzed by ELISPOT assay. Data are presented as the mean ± SD of triplicate assays. Representative data from at least 3 independent experiments with similar results obtained from HD1 are shown. The HLA class II genotype of HD1 is indicated above the panels. The underlined HLA class II alleles encode the HLA class II molecule presenting the peptides to TH cells. B, HLA-DP2–restricted KIF20A60–84-LP–specific bulk TH cells (left) or a TH clone (right) derived from HD2 was established. An HLA-DP–restricted TH clone was cocultured with allogeneic PBMCs derived from HLA-DP2-positive or HLA-DP2-negative donors pulsed/unpulsed with KIF20A60–84-LP. C, KIF20A809–833-LP–specific HLA-DR15–restricted TH cells were generated from a healthy donor (HD1). D, KIF20A809–833-LP–specific HLA-DR53–restricted TH cells were generated from a healthy donor (HD2).

Close modal

To investigate whether KIF20A60–84-LP induces responses in TH cells restricted by other HLA class II molecules, CD4+ T cells from HLA-DR15-negative healthy donors were tested. The TH cells generated from HLA-DP2+ HD2 produced a significant amount of IFN-γ in response to KIF20A60–84-LP–pulsed PBMCs in an HLA-DP–dependent manner. L cells transduced with HLA-DP2 were unavailable; therefore, we established a KIF20A60–84-LP–reactive TH-cell clone (TH clone) and used allogeneic PBMCs from 4 different donors as APCs to determine restriction by shared HLA-DP molecules. We confirmed that KIF20A60–84-LP generates HLA-DP2–restricted TH cells (Fig. 1B). Thus, KIF20A60–84-LP binds to HLA-DR15 and HLA-DP2, which suggests that KIF20A60–84-LP is a promiscuous TH-cell epitope presented by frequent HLA class II molecules (31, 32). In addition, KIF20A60–84-LP could induce antigen-specific and HLA-DR–restricted bulk TH cells from HD3, who was HLA-DR4+ and DR53+, but DR15- and DP2-negative (Supplementary Fig. S2A). Although we were unable to define the HLA class II molecule presenting the LP to the TH cells, this result supports the promiscuous nature of KIF20A60–84-LP.

Next, we assessed whether KIF20A809–833-LP could generate antigen-specific TH cells. The TH cells generated from HLA-DR15+ healthy donors (HD1 and HD4) produced a significant amount of IFN-γ in response to KIF20A809–833-LP–pulsed PBMCs in an HLA-DR–dependent manner (Fig. 1C and Supplementary Fig. S2B). The bulk TH cells specifically recognized L-DR15 cells pulsed with KIF20A809–833-LP in an HLA-DR–dependent manner (Fig. 1C, HD1). CD4+ T cells from an HLA-DR15-negative healthy donor (HD2) were tested to investigate whether KIF20A809–833-LP induces responses in TH cells restricted by other HLA class II molecules. KIF20A809–833-LP could generate HLA-DR53–restricted TH cells in this donor (Fig. 1D). These results show that KIF20A809–833-LP is also a promiscuous TH-cell epitope.

The immunogenicity of KIF20A494–517-LP, which did not include a known CTL epitope was evaluated. KIF20A494–517-LP could generate HLA-DR4–restricted bulk TH cells in HLA-DR4+ HD2 (Supplementary Fig. S2C). Although the immunogenicity of KIF20A494–517-LP was assessed in other donors, it was less immunogenic. Thus, we focused on promiscuous LPs bearing known CTL epitopes, such as KIF20A60–84-LP and KIF20A809–833-LP, for further studies.

KIF20A60–84-LP and KIF20A809–833-LP are naturally processed and presented by dendritic cells

We proceeded to assess whether dendritic cells take up and process the KIF20A protein to stimulate KIF20A-specific TH clones. Dendritic cells loaded with recombinant KIF20A protein were prepared and used as APCs in IFN-γ ELISPOT assays (16, 28). An HLA-DP2–restricted KIF20A60–84-LP–specific TH clone efficiently recognized dendritic cells loaded with KIF20A protein in an HLA-DP–dependent manner, but did not recognize control protein–loaded dendritic cells, indicating that this epitope was naturally processed and presented by HLA-DP2 molecules (Fig. 2A). An HLA-DR53–restricted KIF20A809–833-LP–specific TH clone efficiently recognized dendritic cells loaded with KIF20A protein in an HLA-DR–dependent manner, but did not recognize control protein–loaded dendritic cells, indicating that this epitope was also naturally processed and presented by HLA-DR53 molecules (Fig. 2B).

Figure 2.

Natural processing and presentation of KIF20A-LPs by dendritic cells. A, an HLA-DP2–restricted KIF20A60–84-LP–specific TH clone established from HD2 recognized autologous dendritic cells loaded with a recombinant KIF20A protein. B, an HLA-DR53–restricted KIF20A809–833-LP–specific TH clone established from HD2 recognized autologous dendritic cells loaded with a recombinant KIF20A protein. The relevant KIF20A-derived LP-pulsed dendritic cells were used as positive controls. Representative data from 3 independent experiments with similar results are shown.

Figure 2.

Natural processing and presentation of KIF20A-LPs by dendritic cells. A, an HLA-DP2–restricted KIF20A60–84-LP–specific TH clone established from HD2 recognized autologous dendritic cells loaded with a recombinant KIF20A protein. B, an HLA-DR53–restricted KIF20A809–833-LP–specific TH clone established from HD2 recognized autologous dendritic cells loaded with a recombinant KIF20A protein. The relevant KIF20A-derived LP-pulsed dendritic cells were used as positive controls. Representative data from 3 independent experiments with similar results are shown.

Close modal

KIF20A-LPs stimulate TH1-type CD4+ T cells

To further characterize KIF20A-LP–reactive TH cells, we used the Bio-Plex system to measure the levels of several cytokines released in response to stimulation by the cognate peptide. KIF20A60–84-LP– or KIF20A809–833-LP–specific bulk TH cells from HD2 produced a large amount of TNF-α, IFN-γ, GM-CSF, MIP-1β, and IL-2, but less IL-4 and IL-17 after restimulation with cognate peptide, indicating TH1-polarized characteristics (Fig. 3A). The cytotoxicity marker CD107a was detected on the KIF20A-LPs–specific bulk TH cells stimulated with cognate peptide (Fig. 3B), as was previously showed for antiviral CD4+ effectors and tumor-infiltrating lymphocytes (33–36). These data suggest that KIF20A-specific TH cells provide a helper function and direct cytotoxic activity, both of which are advantageous for cancer immunotherapy.

Figure 3.

Cytokine profile produced by KIF20A-LPs–specific bulk TH cells. A, after 24 hours incubation of TH cells cocultured with autologous PBMCs (for KIF20A60–84-LP–specific bulk TH cells) or L-DR53 (for KIF20A809–833-LP–specific bulk TH cells) in the presence of cognate peptides, the culture supernatant was collected and the concentration of cytokines (TNF-α, IFN-γ, GM-CSF, MIP1β, IL-2, IL-4, and IL-7) was measured using the Bio-Plex assay system. Data are presented as the mean ± SD of triplicate assays. B, detection of CD107a on the cell surface of bulk KIF20A-specific CD4+ T cells after antigenic stimulation. Cells were restimulated with cognate LPs or a control peptide. Events shown are gated for CD4+ T cells. The numbers inside the plots indicate the percentage of the cell population with the quadrant characteristic (CD4+ CD107a+ T cells).

Figure 3.

Cytokine profile produced by KIF20A-LPs–specific bulk TH cells. A, after 24 hours incubation of TH cells cocultured with autologous PBMCs (for KIF20A60–84-LP–specific bulk TH cells) or L-DR53 (for KIF20A809–833-LP–specific bulk TH cells) in the presence of cognate peptides, the culture supernatant was collected and the concentration of cytokines (TNF-α, IFN-γ, GM-CSF, MIP1β, IL-2, IL-4, and IL-7) was measured using the Bio-Plex assay system. Data are presented as the mean ± SD of triplicate assays. B, detection of CD107a on the cell surface of bulk KIF20A-specific CD4+ T cells after antigenic stimulation. Cells were restimulated with cognate LPs or a control peptide. Events shown are gated for CD4+ T cells. The numbers inside the plots indicate the percentage of the cell population with the quadrant characteristic (CD4+ CD107a+ T cells).

Close modal

Enhanced induction of KIF20A-specific CTLs by KIF20A-LP–specific CD4+ T cells

Next, we tested whether KIF20A-LPs could enhance induction of KIF20A-A2809–817 SP–specific CTLs as shown in Fig. 4A. When PBMCs from an HLA-A2+/DP2+/DR53+ donor (HD2) were stimulated with KIF20A-A2809–817 SP alone (SP), the frequency of KIF20A-A2809–817 SP-specific tetramer+ cells was 0.24% of CD8+ T cells (Fig. 4B). Addition of KIF20A60–84-LP (LP) into the SP culture (SP + LP) induced a slight increase in the frequency of tetramer+ cells. In contrast, when the PBMCs were costimulated with KIF20A-A2809–817 SP, KIF20A60–84-LP, and KIF20A60–84-LP–specific TH clone (SP + LP + TH clone), the frequency of KIF20A-A2809–817 SP-specific CTLs increased significantly to 0.87%. As shown in Supplementary Fig. S3A and S3B, KIF20A809–833-LP alone (LP), which encompasses KIF20A-A2809–817 SP, or addition of KIF20A809–833-LP into the SP culture (SP + LP) induced a slight increase in the frequency of KIF20A-A2809–817 SP-specific CTLs. However, the KIF20A809–833-LP–specific TH clone rapidly increased in response to the KIF20A809–833-LP when we added both LP and TH clone into the PBMCs without KIF20A-A2809–817 SP (LP + TH clone) and then we could not detect the increase of frequency of KIF20A-A2809–817 SP–specific CTLs. We also observed that the stimulation of PBMCs with KIF20A-A2809–817 SP, KIF20A809–833-LP, and KIF20A809–833-LP–specific TH clone (SP + LP + TH clone) most strongly enhanced induction of KIF20A-A2809–817 SP–specific tetramer+ T cells. These results indicate that the activated TH1 cells enhanced induction of KIF20A-specific CTLs in the presence of KIF20A-A2809–817 SP.

Figure 4.

KIF20A-LPs induce efficient expansion of KIF20A-specific CTLs in vitro and in vivo. A, enhanced induction of KIF20A-A2809–817 SP–specific CTLs in response to stimulation with KIF20A60–84-LP and KIF20A60–84-LP–specific TH clones. PBMCs obtained from HLA-A2+/DP2+ HD2, from which an HLA-DP2–restricted KIF20A60–84-LP–specific CD4+ TH clone was generated, were cultured for 11 days with KIF20A-A2809–817 SP (SP), SP + KIF20A60–84-LP (LP), or SP + LP + KIF20A60–84-LP–specific TH clone (TH clone). On day 11, the cells were stained with KIF20A-A2809–817 SP–specific tetramer with an anti-human CD8 mAb and analyzed by flow cytometry. B, representative KIF20A-A2809–817 SP–specific tetramer staining (gated on CD8+ T cells) obtained from 3 independent experiments with similar results has been shown. C, the KIF20A809–833-LP stimulated KIF20A-A2809–817 SP–specific CD8+ T cells in vitro. The number of IFN-γ–producing KIF20A-A2809–817 SP–specific bulk CTL in response to stimulation with the KIF20A809–833-LP–loaded or control LP–loaded autologous dendritic cells was counted by ELISPOT assay. Statistically significant differences (P < 0.05) are indicated with asterisks. Representative data from 3 independent experiments with similar results are shown. D, PBMCs from HLA-A24+ donors (HD4 and HD8) were incubated with KIF20A60–84-LP for 2 weeks. On days 0 and 7, KIF20A60–84-LP was added. On day 14, the cells were harvested and the number of IFN-γ-producing T cells (1 × 105 cells/well) in response to stimulation with KIF20A-A2466–75 SP–pulsed C1R-A2402 cells (2 × 104 cells/well) was counted by ELISPOT assay. Representative data from 5 independent experiments with similar results are shown.

Figure 4.

KIF20A-LPs induce efficient expansion of KIF20A-specific CTLs in vitro and in vivo. A, enhanced induction of KIF20A-A2809–817 SP–specific CTLs in response to stimulation with KIF20A60–84-LP and KIF20A60–84-LP–specific TH clones. PBMCs obtained from HLA-A2+/DP2+ HD2, from which an HLA-DP2–restricted KIF20A60–84-LP–specific CD4+ TH clone was generated, were cultured for 11 days with KIF20A-A2809–817 SP (SP), SP + KIF20A60–84-LP (LP), or SP + LP + KIF20A60–84-LP–specific TH clone (TH clone). On day 11, the cells were stained with KIF20A-A2809–817 SP–specific tetramer with an anti-human CD8 mAb and analyzed by flow cytometry. B, representative KIF20A-A2809–817 SP–specific tetramer staining (gated on CD8+ T cells) obtained from 3 independent experiments with similar results has been shown. C, the KIF20A809–833-LP stimulated KIF20A-A2809–817 SP–specific CD8+ T cells in vitro. The number of IFN-γ–producing KIF20A-A2809–817 SP–specific bulk CTL in response to stimulation with the KIF20A809–833-LP–loaded or control LP–loaded autologous dendritic cells was counted by ELISPOT assay. Statistically significant differences (P < 0.05) are indicated with asterisks. Representative data from 3 independent experiments with similar results are shown. D, PBMCs from HLA-A24+ donors (HD4 and HD8) were incubated with KIF20A60–84-LP for 2 weeks. On days 0 and 7, KIF20A60–84-LP was added. On day 14, the cells were harvested and the number of IFN-γ-producing T cells (1 × 105 cells/well) in response to stimulation with KIF20A-A2466–75 SP–pulsed C1R-A2402 cells (2 × 104 cells/well) was counted by ELISPOT assay. Representative data from 5 independent experiments with similar results are shown.

Close modal

Next, we examined that the CD107a expression of KIF20A-A2466–75 SP–specific CTLs cultured in the presence of KIF20A809–833-LP–specific TH cells stimulated with the relevant LP for 1 week to assess the function of KIF20A-specific CTLs expanded by activated KIF20A-specific TH cells. KIF20A809–833-LP–specific bulk CD4+ T cells and KIF20A-A2466–75 SP–specific bulk CD8+ T cells derived from HLA-A24+ and HLA-DR15+ HD4 were cultured with autologous dendritic cells in the presence of KIF20A-A2466–75 SP (SP alone), KIF20A-A2466–75 SP + Control LP (Control LP + SP), or KIF20A-A2466–75 SP + KIF20A809–833-LP (KIF20A809–833-LP + SP) without addition of any cytokine. After 1-week in vitro culture with peptides, the cultured cells were stained with tetramer of the HLA-A*24:02/KIF20A-A2467–75 complex, anti-human CD107a mAb, and anti-human CD8 mAb as described in the Supplementary Materials and Methods section. As shown in Supplementary Fig. S3C, the addition of KIF20A-A2466–75 SP + KIF20A809–833-LP (KIF20A809–833-LP + SP) significantly increased the absolute number of KIF20A-A2466–75 SP–specific CD8+ T cells compared with the addition of KIF20A-A2466–75 SP alone (SP) or KIF20A-A2466–75 SP + Control LP (Control LP + SP). The absolute number of KIF20A-A2466–75 SP–specific CTLs expressing CD107a on the cell surface after restimulation with KIF20A-A2466–75 SP was also significantly augmented by the addition of KIF20A-A2466–75 SP + KIF20A809–833-LP (KIF20A809–833-LP + SP; Supplementary Fig. S3D). These results suggest that activated KIF20A-LP–specific TH cells enhance induction of KIF20A-A2466–75 SP–specific CTLs expressing CD107a.

KIF20A-LPs stimulate KIF20A-specific CD8+ T-cells in vitro and in vivo

We assessed whether the KIF20A-LPs bearing CTL epitopes could stimulate KIF20A-SP–specific CTLs. The capacity of KIF20A809–833-LP to stimulate KIF20A-A2809–817 SP–specific CTLs was examined by IFN-γ ELISPOT assay as described in the Materials and Methods section. As shown in Fig. 4C, KIF20A-A2809–817 SP–reactive bulk CTLs from an HLA-A2+ and -DR53+ donor (HD5) specifically produced IFN-γ in response to stimulation with KIF20A809–833-LP–loaded dendritic cell, but not with control LP-loaded dendritic cell. The specific IFN-γ production was significantly inhibited by addition of the anti–HLA class I mAb, but not by the anti–HLA-DR mAb, thus suggesting that KIF20A-A2809–817 SP–reactive CTLs were stimulated through the cross-presentation of KIF20A809–833-LP by dendritic cells in vitro.

Subsequently, the capacity of KIF20A60–84-LP to induce KIF20A-A2466–75 SP–specific CTLs was examined by IFN-γ ELISPOT assay. After in vitro stimulation of PBMCs with KIF20A60–84-LP for 2 weeks, the cells were harvested and the number of IFN-γ–producing T cells in response to stimulation with KIF20A-A2466–75 SP–pulsed C1R-A2402 cells was counted by ELISPOT assay. Details are provided in Supplementary Materials and Methods. As shown in Fig. 4D, KIF20A-A2466–75 SP–specific CTLs were induced in PBMCs cultured with KIF20A60–84-LP. In addition, KIF20A809–833-LP also induced KIF20A-A2809–817 SP–specific CTLs from PBMCs derived from HLA-A2+ donors (HD2 and HD3; data not shown).

The capacity of KIF20A60–84-LP to prime KIF20A-A2466–75 SP–specific CTLs in vivo was examined by an ex vivo IFN-γ ELISPOT assay. HLA-A24 Tgm were immunized three times with KIF20A60–84-LP. The CD8+ T cells of HLA-A24 Tgm vaccinated with KIF20A60–84-LP produced IFN-γ in response to stimulation with bone marrow–dendritic cells pulsed with the KIF20A-A2466–75 SP (Supplementary Fig. S4). These results suggest that after uptake of KIF20A60–84-LP, APCs cross-prime KIF20A-A2466–75 SP–specific CTLs in vitro and in vivo.

Presence of KIF20A-specifc TH1 cells in patients with HNMT receiving immunotherapy with TAA-derived CTL-epitope peptides

To the best of our knowledge, no studies have examined KIF20A expression in HNMT. Immunohistochemical analysis of KIF20A expression was done on 56 cases of HNMT (39 squamous cell carcinoma, 14 adenoid cystic carcinoma, 2 osteosarcoma, and 1 angiosarcoma tissue specimens). Twenty-six of the 39 head and neck squamous cell carcinomas (67%), 4 of the 14 adenoid cystic carcinomas (29%), and 1 of the 2 osteosarcoma (50%) showed positive expression of KIF20A. (Supplementary Table S3). No staining was detected in the benign tumor samples.

In context of cancer immunotherapy, there is strong evidence suggesting that vaccines using restricted epitopes can result in broad CD8+ T-cell responses to antigens not presented in the vaccine (37–39). Thus, we considered that KIF20A-specific TH-cell responses may be induced by vaccination with TAA-derived CTL-epitope peptides, which do not include KIF20A-derived SPs. We assessed T-cell responses specific for KIF20A in peripheral blood from 16 patients who were receiving immunotherapy for treatment of HNMT. The donor characteristics are summarized in Table 1. After 1 week of in vitro stimulation of PBMCs with KIF20A-LPs, the frequency of individual KIF20A-LP–specific T cells was detected by IFN-γ ELISPOT assay (Fig. 5A). PBMCs isolated from 9 healthy volunteers were used as controls. Responses were considered positive when the number of IFN-γ–secreting cells was at least twofold above the negative control. KIF20A-specific TH-cell responses were observed in 8 of 16 patients (KIF20A60–84-LP, 2 of 16, 13%; KIF20A809–833-LP, 7 of 16, 44%), but no specific immune responses to KIF20A-LPs were detected in the 9 healthy donors (Table 1). We also found that the number of specific spots against KIF20A60–84-LP and KIF20A809–833-LP in patients were significantly larger than in healthy donors (Fig. 5B). KIF20A809–833-LP–specific IFN-γ production by T cells in HNMT31 and HNMT43 was significantly inhibited by addition of anti-HLA-DR mAb but not by anti–HLA class I mAb (Fig. 5C). Interestingly, specific responses to KIF20A809–833-LP were augmented in some patients (HNMT31 and HNMT42), or induced in HNMT43 during the course of immunotherapy (Fig. 5D). As shown in Fig. 5E, KIF20A antigen was expressed in patients with HNMT in whom KIF20A-specific TH1 cell responses were detected (Table 1; HNMT31 and HNMT108), but was not expressed in those for whom KIF20A-specific TH1 cell responses were not detected (Table 1; HNC102 and 107). These observations suggest that APCs collected and processed a KIF20A antigen derived from tumor cells expressing KIF20A, and then activated KIF20A-specific TH1 cells in vivo.

Figure 5.

Presence of KIF20A-LPs–specific TH cells in PBMCs isolated from patients with HNMT receiving immunotherapy with TAA-derived CTL-epitope peptides. A, after in vitro stimulation of PBMCs with a mixture of KIF20A60–84-LP and KIF20A809–833-LP for 1 week, the frequency of individual KIF20A-LPs–specific T cells was detected by IFN-γ ELISPOT assay. B, KIF20A-LPs–specific TH1 cell responses were assessed in 16 patients with HNMT receiving immunotherapy and in 9 healthy donors. The results represent specific IFN-γ spots after background subtraction. Each dot represents an individual donor. Horizontal lines denote median values, and P values represent statistical results from a nonparametric Mann–Whitney U test. C, HLA class II restriction of the IFN-γ–producing KIF20A809–833-LP–specific TH cells in HNMT31 and HNMT43. PBMCs stimulated with LPs for 1 week were restimulated with KIF20A809–833-LP in the presence of mAbs specific to HLA-DR, HLA-DP, HLA-DQ, or HLA class I. D, KIF20A-LPs–specific TH1 cell responses in patients with HNMT were detected during the course of immunotherapy. E, immunohistochemical analyses of the KIF20A protein in cancer tissues and osteosarcoma (original magnification × 400). Positive KIF20A immunohistochemical staining on tissue sections of adenoid cystic carcinoma in HNMT31 and osteosarcoma in HNMT108 are shown. Negative KIF20A immunohistochemical staining on tissue sections of squamous cell carcinoma in HNMT102 and osteosarcoma in HNMT107 are also shown. Malignant cells positive for KIF20A showed homogeneous cytoplasmic staining. Expression of KIF20A in HNMT tissues was associated with KIF20A-LPs–specific TH1-cell responses in patients with HNMT.

Figure 5.

Presence of KIF20A-LPs–specific TH cells in PBMCs isolated from patients with HNMT receiving immunotherapy with TAA-derived CTL-epitope peptides. A, after in vitro stimulation of PBMCs with a mixture of KIF20A60–84-LP and KIF20A809–833-LP for 1 week, the frequency of individual KIF20A-LPs–specific T cells was detected by IFN-γ ELISPOT assay. B, KIF20A-LPs–specific TH1 cell responses were assessed in 16 patients with HNMT receiving immunotherapy and in 9 healthy donors. The results represent specific IFN-γ spots after background subtraction. Each dot represents an individual donor. Horizontal lines denote median values, and P values represent statistical results from a nonparametric Mann–Whitney U test. C, HLA class II restriction of the IFN-γ–producing KIF20A809–833-LP–specific TH cells in HNMT31 and HNMT43. PBMCs stimulated with LPs for 1 week were restimulated with KIF20A809–833-LP in the presence of mAbs specific to HLA-DR, HLA-DP, HLA-DQ, or HLA class I. D, KIF20A-LPs–specific TH1 cell responses in patients with HNMT were detected during the course of immunotherapy. E, immunohistochemical analyses of the KIF20A protein in cancer tissues and osteosarcoma (original magnification × 400). Positive KIF20A immunohistochemical staining on tissue sections of adenoid cystic carcinoma in HNMT31 and osteosarcoma in HNMT108 are shown. Negative KIF20A immunohistochemical staining on tissue sections of squamous cell carcinoma in HNMT102 and osteosarcoma in HNMT107 are also shown. Malignant cells positive for KIF20A showed homogeneous cytoplasmic staining. Expression of KIF20A in HNMT tissues was associated with KIF20A-LPs–specific TH1-cell responses in patients with HNMT.

Close modal
Table 1.

Clinical characteristics of HNMT patients

KIF20A-specific CD4+ T-cell responsesa
Patient IDAge/sexKIF20A60-84-LPKIF20A809-833-LPHistologic subtypeIHC analysis of KIF20AHLA-DRB1HLA-DRB4HLA-DPB1
Positive/totalStaining
2/16 (13%)7/16 (44%)
CTR-8379 
HNMT10 61/M   Squamous cell carcinoma n.t. 01:01/04:05 DR53 05:01/− 
HNMT20 57/F − + Squamous cell carcinoma n.t. 01:01/09:01 DR53 02:01/05:01 
HNMT26 70/M − − Basaloid squamous cell carcinoma n.t. 04:05/15:02 DR53 05:01/09:01 
HNMT29 64/F − − Squamous cell carcinoma n.t. 09:01/14:54 DR53 03:01/05:01 
HNMT31 69/F − + Adenoid cystic carcinoma Positive 01:01/11:01 02:01/04:02 
HNMT34 65/M − + Squamous cell carcinoma n.t. 08:03/15:02 02:01/05:01 
HNMT35 85/F − + Squamous cell carcinoma n.t. 04:05/08:02 DR53 05:01/− 
HNMT39 77/M − − Adenoid cystic carcinoma n.t. 04:06/14:54 DR53 05:01/19:01 
HNMT40 76/M − − Squamous cell carcinoma n.t. 01:01/09:01 DR53 04:02/05:01 
HNMT41 51/F + + Adenoid cystic carcinoma n.t. 01:01/04:05 DR53 04:02/05:01 
HNMT42 36/F − + Unknown n.t. 01:01/08:02 04:02/05:01 
HNMT43 50/M − + Squamous cell carcinoma n.t. 08:02/09:01 DR53 05:01/− 
CTR-8380 
HNMT102 80/F − − Squamous cell carcinoma Negative 15:02/− – 02:01/09:01 
HNMT105 65/M − − Angiosarcoma Negative 04:05/13:02 DR53 03:01/04:01 
HNMT107 20/M − − Osteosarcoma Negative 09:01/− DR53 02:01/02:02 
HNMT108 41/M + − Osteosarcoma Positive 04:05/09:01 DR53 05:01/− 
KIF20A-specific CD4+ T-cell responsesa
Patient IDAge/sexKIF20A60-84-LPKIF20A809-833-LPHistologic subtypeIHC analysis of KIF20AHLA-DRB1HLA-DRB4HLA-DPB1
Positive/totalStaining
2/16 (13%)7/16 (44%)
CTR-8379 
HNMT10 61/M   Squamous cell carcinoma n.t. 01:01/04:05 DR53 05:01/− 
HNMT20 57/F − + Squamous cell carcinoma n.t. 01:01/09:01 DR53 02:01/05:01 
HNMT26 70/M − − Basaloid squamous cell carcinoma n.t. 04:05/15:02 DR53 05:01/09:01 
HNMT29 64/F − − Squamous cell carcinoma n.t. 09:01/14:54 DR53 03:01/05:01 
HNMT31 69/F − + Adenoid cystic carcinoma Positive 01:01/11:01 02:01/04:02 
HNMT34 65/M − + Squamous cell carcinoma n.t. 08:03/15:02 02:01/05:01 
HNMT35 85/F − + Squamous cell carcinoma n.t. 04:05/08:02 DR53 05:01/− 
HNMT39 77/M − − Adenoid cystic carcinoma n.t. 04:06/14:54 DR53 05:01/19:01 
HNMT40 76/M − − Squamous cell carcinoma n.t. 01:01/09:01 DR53 04:02/05:01 
HNMT41 51/F + + Adenoid cystic carcinoma n.t. 01:01/04:05 DR53 04:02/05:01 
HNMT42 36/F − + Unknown n.t. 01:01/08:02 04:02/05:01 
HNMT43 50/M − + Squamous cell carcinoma n.t. 08:02/09:01 DR53 05:01/− 
CTR-8380 
HNMT102 80/F − − Squamous cell carcinoma Negative 15:02/− – 02:01/09:01 
HNMT105 65/M − − Angiosarcoma Negative 04:05/13:02 DR53 03:01/04:01 
HNMT107 20/M − − Osteosarcoma Negative 09:01/− DR53 02:01/02:02 
HNMT108 41/M + − Osteosarcoma Positive 04:05/09:01 DR53 05:01/− 

Abbreviations: CTR, clinical trials registry; DR53, DRB4*01:03; IHC, immunohistochemistry; M/F, male/female; n.t., not tested.

aKIF20A-specific T-cell responses measured by IFN-γ ELISPOT assay as detailed in the Materials and Methods section. Positive and negative responses are denoted by (+) and (−), respectively. The underlined HLA class II alleles encode HLA class II molecules presenting KIF20A-LP to TH cells in healthy donors (Fig. 1; HLA-DRB1*15:02, DR53, and DPB1*02:01).

We identified 2 promiscuous KIF20A-derived TH-cell epitopes bearing known HLA-A2– or HLA-A24–restricted CTL epitopes. KIF20A-specific CTLs were induced by stimulation with KIF20A-LPs in vitro and in vivo. This is the first demonstration of KIF20A expression in HNMT, and the presence of KIF20A-specific TH1-cell responses in patients with HNMT. Furthermore, these responses were related to KIF20A expression in HNMT tissues. We postulate that these KIF20A-LPs–specific TH1-cell responses may occur through the KIF20A antigen in apoptotic bodies released from tumor cells. When collected and processed by APCs, the KIF20A antigen most probably activates KIF20A-specific TH1 cells in vivo.

Recent reports showed that a new wave of tumor-specific CTL clones became detectable in the blood after vaccination and provide convincing evidence that the phenomenon of antigen spreading is critical to the development of effective antitumor immunity (37–41). The interaction between antivaccine CTLs and the tumor facilitates stimulation of large numbers of antitumor CTLs that proceed to destroy the tumor cells. However, CD4+ T-cell responses against a TAA in tumor-bearing patients vaccinated with CTL-epitope peptides have not been investigated in detail. In this study, we analyzed CD4+ T-cell responses to a KIF20A antigen, which was not present in the vaccine cocktail, in the patient's blood before and after vaccination to investigate the phenomenon of antigen spreading triggered by CTL-epitope vaccination. In patient HNMT43 with advanced cancer, the KIF20A809–833-LP–specific TH1 response was absent before vaccination, but after vaccination this response was significantly induced (Fig. 5D, right panel). We believe that this KIF20A809–833-LP–specific TH1-cell response is a phenomenon of antigen spreading triggered by vaccination with CTL epitopes.

Aarntzen and colleagues have recently reported that targeting TH cells with dendritic cells pulsed with both HLA class I- and II-restricted epitopes enhances vaccine-specific immunologic responses and improves clinical responses (42). We showed that KIF20A-LPs and TH1 clones enhanced induction of HLA-A2–restricted KIF20A-specific CTLs in vitro. These findings indicate that KIF20A-LPs can augment the induction of antigen-specific CTLs in combination with immunotherapy using KIF20A CTL-epitope peptides. We speculate that immunotherapy with peptide vaccinations using KIF20A-LPs and KIF20A-SPs may improve clinical outcomes in KIF20A-expressing cancer.

HLA class II restriction of the KIF20A809–833-LP–specific CD4+ T-cell response in HNMT31 was confirmed by inhibition of IFN-γ secretion in the presence of HLA-DR–blocking antibody (Fig. 5C), although HLA-DR alleles of HNMT31 (Table 1; DRB1*01:01/11:01) were not shared by the HLA-DR alleles, which encode HLA class II molecules presenting KIF20A809–833-LP to TH cells in healthy donors (HLA-DR15 and DR53; Fig. 1). This result supports the promiscuous nature of KIF20A809–833-LP and indicates that LP is naturally processed and presented by HLA class II molecules in vivo.

In this study, significant frequencies of KIF20A-specific TH1-cell responses were detected in patients with HNMT receiving immunotherapy (8 of 16, 50%). Godet and colleagues reported a possible synergistic effect of the telomerase-specific CD4+ T-cell response with chemotherapy in lung cancer. They showed that the existence of spontaneous telomerase-specific TH1 cells before first-line chemotherapy significantly increased overall survival in lung cancer that responded to chemotherapy (43). In addition, the recent introduction of immunotherapy in clinical practice emphasized the influence of immune responses on cancer prognosis and chemotherapy effectiveness (11, 12, 44). These pieces of evidence support the hypothesis that induction of KIF20A-specific TH1 cells by KIF20A-LP vaccination may improve the clinical outcome of cancer patients when combined with chemotherapy or other standard therapies (45–47). Weide and colleagues have recently reported that the presence of circulating TH1 cells responding to Melan-A or NY-ESO-1 had a strong prognostic impact on survival among chemotherapy-treated advanced melanoma patients (48). Thus, KIF20A-LPs–specific TH1-cell responses in patients with HNMT receiving immunotherapy may positively influence overall survival. The impact of KIF20A-specific TH1-cell responses on clinical outcome will be evaluated in a future study.

Recent studies of LPs have shown that vaccines containing natural CTL epitopes were superior to those comprising minimal CTL epitopes in antitumor CTL immunity because of long-lasting cross-presentation of the LPs (10, 49). We showed that KIF20A-LPs stimulated KIF20A-specific CTLs in vitro and in vivo. However, we did not compare the capacity to induce KIF20A-specific CTLs between KIF20A-LPs and KIF20A-SPs in human cells. In vivo assay using HLA-A24 Tgm, vaccination with KIF20A60–84-LP was not superior to KIF20A-A2466–75 SP in induction of KIF20A-specific CTLs (data not shown). Therefore, we are not able to conclude that we should use KIF20A-LP encompassing CTL epitope alone or both KIF20A-SP and the KIF20A-LP to elicit stronger antitumor T-cell immunity at this moment. These issues will be evaluated in a future study.

In this study, we did not confirm the response of generated TH cells to the shorter, 15-mer TH epitope from KIF20A-LPs, because we considered that these 25-mer amino acid long KIF20A-LPs encompass both HLA class I– and class II–restricted T-cell epitopes including unconfirmed T-cell epitopes by in vitro experiments and could cover many cancer patients. Based on the findings from healthy donors, 2 KIF20A-derived LPs, KIF20A60–84-LP and KIF20A809–833-LP, cover at least 93% of Japanese individuals. We are planning to use these 25-mer KIF20A-LPs in a future clinical trial of peptide-based immunotherapy.

In conclusion, we identified promiscuous TH-cell epitopes derived from KIF20A and present the first clinical evaluation of KIF20A-specific TH1-cell responses in patients with HNMT receiving immunotherapy. These TH-cell epitopes provide a tool for propagation of KIF20A-specific TH1 cells and CTLs. These findings support a clinical trial of KIF20A peptide–based immunotherapy for cancer treatment.

K. Yoshida and T. Tsunoda are employed (other than primary affiliation; e.g., consulting) by OncoTherapy Science, Inc. Y. Nakamura is a stockholder and scientific advisor for OncoTherapy Science, Inc. Y. Nishimura has a commercial research grant from OncoTherapy Science, Inc. No potential conflicts of interest were disclosed by the other authors.

Conception and design: Y. Tomita, H. Tsukamoto, Y. Nishimura

Development of methodology: Y. Tomita, A. Yuno, H. Tsukamoto, A. Irie

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Tomita, A. Yuno, Y. Kuroda, M. Hirayama, A. Irie, K. Kawahara, J. Yatsuda, A. Hamada, H. Jono, K. Yoshida, Y. Yoshitake, M. Shinohara

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Tomita, A. Yuno, M. Hirayama, A. Irie, K. Kawahara, J. Yatsuda

Writing, review, and/or revision of the manuscript: Y. Tomita, A. Yuno, Y. Nishimura

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Tomita, A. Yuno, S. Senju, Y. Kuroda, T. Tsunoda, H. Kohrogi, Y. Nishimura

Study supervision: Y. Tomita, H. Tsukamoto, S. Senju, Y. Nakamura, Y. Nishimura

The authors thank Mr. R. Nishikata (Department of Immunogenetics, Kumamoto University) for his technical assistance and Ms. T. Kubo (Department of Molecular Pathology, Kumamoto University) for technical assistance with immunohistochemical analyses.

This research was supported by MEXT KAKENHI Grant No. 22133005; JSPS KAKENHI Grant No. 24300334, a research grant from the Princess Takamatsu Cancer Research Fund No. 10-24215, and funding from OncoTherapy Science, Inc.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Imai
K
,
Hirata
S
,
Irie
A
,
Senju
S
,
Ikuta
Y
,
Yokomine
K
, et al
Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
.
Br J Cancer
2011
;
104
:
300
7
.
2.
Yamashita
J
,
Fukushima
S
,
Jinnin
M
,
Honda
N
,
Makino
K
,
Sakai
K
, et al
Kinesin family member 20A is a novel melanoma-associated antigen
.
Acta Derm Venereol
2012
;
92
:
593
7
.
3.
Claerhout
S
,
Lim
JY
,
Choi
W
,
Park
YY
,
Kim
K
,
Kim
SB
, et al
Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer
.
PLoS One
2011
;
6
:
e24662
.
4.
Osawa
R
,
Tsunoda
T
,
Yoshimura
S
,
Watanabe
T
,
Miyazawa
M
,
Tani
M
, et al
Identification of HLA-A24-restricted novel T cell epitope peptides derived from P-cadherin and kinesin family member 20A
.
J Biomed Biotechnol
2012
;
2012
:
848042
.
5.
Chamoto
K
,
Tsuji
T
,
Funamoto
H
,
Kosaka
A
,
Matsuzaki
J
,
Sato
T
, et al
Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells
.
Cancer Res
2004
;
64
:
386
90
.
6.
Bevan
MJ
. 
Helping the CD8(+) T-cell response
.
Nat Rev Immunol
2004
;
4
:
595
602
.
7.
Shedlock
DJ
,
Shen
H
. 
Requirement for CD4 T cell help in generating functional CD8 T cell memory
.
Science
2003
;
300
:
337
9
.
8.
Street
SE
,
Cretney
E
,
Smyth
MJ
. 
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis
.
Blood
2001
;
97
:
192
7
.
9.
Bos
R
,
Sherman
LA
. 
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes
.
Cancer Res
2010
;
70
:
8368
77
.
10.
Melief
CJ
,
van der Burg
SH
. 
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
.
Nat Rev Cancer
2008
;
8
:
351
60
.
11.
Brunsvig
PF
,
Kyte
JA
,
Kersten
C
,
Sundstrom
S
,
Moller
M
,
Nyakas
M
, et al
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
.
Clin Cancer Res
2011
;
17
:
6847
57
.
12.
Kyte
JA
,
Gaudernack
G
,
Dueland
S
,
Trachsel
S
,
Julsrud
L
,
Aamdal
S
. 
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
.
Clin Cancer Res
2011
;
17
:
4568
80
.
13.
Kenter
GG
,
Welters
MJ
,
Valentijn
AR
,
Lowik
MJ
,
Berends-van der Meer
DM
,
Vloon
AP
, et al
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
.
N Engl J Med
2009
;
361
:
1838
47
.
14.
Kono
K
,
Iinuma
H
,
Akutsu
Y
,
Tanaka
H
,
Hayashi
N
,
Uchikado
Y
, et al
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
.
J Transl Med
2012
;
10
:
141
.
15.
Suda
T
,
Tsunoda
T
,
Daigo
Y
,
Nakamura
Y
,
Tahara
H
. 
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy
.
Cancer Sci
2007
;
10
:
1803
8
.
16.
Harao
M
,
Hirata
S
,
Irie
A
,
Senju
S
,
Nakatsura
T
,
Komori
H
, et al
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL
.
Int J Cancer
2008
;
123
:
2616
25
.
17.
Tomita
Y
,
Imai
K
,
Senju
S
,
Irie
A
,
Inoue
M
,
Hayashida
Y
, et al
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells
.
Cancer Sci
2011
;
102
:
697
705
.
18.
Wang
P
,
Sidney
J
,
Kim
Y
,
Sette
A
,
Lund
O
,
Nielsen
M
, et al
Peptide binding predictions for HLA DR, DP and DQ molecules
.
BMC Bioinform
2010
;
11
:
568
.
19.
Wang
P
,
Sidney
J
,
Dow
C
,
Mothe
B
,
Sette
A
,
Peters
B
. 
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach
.
PLoS Comput Biol
2008
;
4
:
e1000048
.
20.
Demachi-Okamura
A
,
Ito
Y
,
Akatsuka
Y
,
Tsujimura
K
,
Morishima
Y
,
Takahashi
T
, et al
Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells
.
Cancer Sci
2008
;
99
:
1633
42
.
21.
Ramduth
D
,
Day
CL
,
Thobakgale
CF
,
Mkhwanazi
NP
,
de Pierres
C
,
Reddy
S
, et al
Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection
.
PLoS One
2009
;
4
:
e5013
.
22.
Zarour
HM
,
Storkus
WJ
,
Brusic
V
,
Williams
E
,
Kirkwood
JM
. 
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
.
Cancer Res
2000
;
60
:
4946
52
.
23.
Tabata
H
,
Kanai
T
,
Yoshizumi
H
,
Nishiyama
S
,
Fujimoto
S
,
Matsuda
I
, et al
Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus
.
Hum Immunol
1998
;
59
:
549
60
.
24.
Monji
M
,
Nakatsura
T
,
Senju
S
,
Yoshitake
Y
,
Sawatsubashi
M
,
Shinohara
M
, et al
Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses
.
Clin Cancer Res
2004
;
10
:
6047
57
.
25.
Yokomine
K
,
Senju
S
,
Nakatsura
T
,
Irie
A
,
Hayashida
Y
,
Ikuta
Y
, et al
The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy
.
Int J Cancer
2010
;
126
:
2153
63
.
26.
Inoue
M
,
Senju
S
,
Hirata
S
,
Irie
A
,
Baba
H
,
Nishimura
Y
. 
An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice
.
Immunol Lett
2009
;
126
:
67
72
.
27.
Yoshitake
Y
,
Nakatsura
T
,
Monji
M
,
Senju
S
,
Matsuyoshi
H
,
Tsukamoto
H
, et al
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis
.
Clin Cancer Res
2004
;
10
:
6437
48
.
28.
Tomita
Y
,
Harao
M
,
Senju
S
,
Imai
K
,
Hirata
S
,
Irie
A
, et al
Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells
.
Cancer Sci
2011
;
102
:
71
8
.
29.
Imai
K
,
Hirata
S
,
Irie
A
,
Senju
S
,
Ikuta
Y
,
Yokomine
K
, et al
Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers
.
Clin Cancer Res
2008
;
14
:
6487
95
.
30.
Britten
CM
,
Janetzki
S
,
Butterfield
LH
,
Ferrari
G
,
Gouttefangeas
C
,
Huber
C
, et al
T cell assays and MIATA: the essential minimum for maximum impact
.
Immunity
2012
;
37
:
1
2
.
31.
Saito
S
,
Ota
S
,
Yamada
E
,
Inoko
H
,
Ota
M
. 
Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population
.
Tissue Antigens
2000
;
56
:
522
9
.
32.
Mack
SJ
,
Bugawan
TL
,
Moonsamy
PV
,
Erlich
JA
,
Trachtenberg
EA
,
Paik
YK
, et al
Evolution of Pacific/Asian populations inferred from HLA class II allele frequency distributions
.
Tissue Antigens
2000
;
55
:
383
400
.
33.
Casazza
JP
,
Betts
MR
,
Price
DA
,
Precopio
ML
,
Ruff
LE
,
Brenchley
JM
, et al
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation
.
J Exp Med
2006
;
203
:
2865
77
.
34.
Attig
S
,
Hennenlotter
J
,
Pawelec
G
,
Klein
G
,
Koch
SD
,
Pircher
H
, et al
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas
.
Cancer Res
2009
;
69
:
8412
9
.
35.
Widenmeyer
M
,
Griesemann
H
,
Stevanovic
S
,
Feyerabend
S
,
Klein
R
,
Attig
S
, et al
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
.
Int J Cancer
2012
;
131
:
140
9
.
36.
Martorelli
D
,
Muraro
E
,
Merlo
A
,
Turrini
R
,
Rosato
A
,
Dolcetti
R
. 
Role of CD4 +cytotoxic T lymphocytes in the control of viral diseases and cancer
.
Int Rev Immunol
2010
;
29
:
371
402
.
37.
Corbière
V
,
Chapiro
J
,
Stroobant
V
,
Ma
W
,
Lurquin
C
,
Lethé
B
, et al
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases
.
Cancer Res
2011
;
71
:
1253
62
.
38.
Ribas
A
,
Timmerman
JM
,
Butterfield
LH
,
Economou
JS
. 
Determinant spreading and tumor responses after peptide-based cancer immunotherapy
.
Trends Immunol
2003
;
24
:
58
61
.
39.
Hunder
NN
,
Wallen
H
,
Cao
J
,
Hendricks
DW
,
Reilly
JZ
,
Rodmyre
R
, et al
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
.
N Engl J Med
2008
;
358
:
2698
703
.
40.
Germeau
C
,
Ma
W
,
Schiavetti
F
,
Lurquin
C
,
Henry
E
,
Vigneron
N
, et al
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
.
J Exp Med
2005
;
201
:
241
8
.
41.
Lurquin
C
,
Lethe
B
,
De Plaen
E
,
Corbiere
V
,
Theate
I
,
van Baren
N
, et al
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen
.
J Exp Med
2005
;
201
:
249
57
.
42.
Aarntzen
EH
,
De Vries
IJ
,
Lesterhuis
WJ
,
Schuurhuis
D
,
Jacobs
JF
,
Bol
K
, et al
Targeting CD4+ T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination
.
Cancer Res
2013
;
73
:
19
29
.
43.
Godet
Y
,
Fabre
E
,
Dosset
M
,
Lamuraglia
M
,
Levionnois
E
,
Ravel
P
, et al
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response
.
Clin Cancer Res
2012
;
18
:
2943
53
.
44.
Robert
C
,
Thomas
L
,
Bondarenko
I
,
O'Day
S
,
Weber
J
,
Garbe
C
, et al
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
.
N Engl J Med
2011
;
364
:
2517
26
.
45.
Ding
ZC
,
Zhou
G
. 
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects
.
Clin Dev Immunol
2012
;
2012
:
890178
.
46.
Lesterhuis
WJ
,
Haanen
JB
,
Punt
CJ
. 
Cancer immunotherapy—revisited
.
Nat Rev Drug Discov
2011
;
10
:
591
600
.
47.
Walter
S
,
Weinschenk
T
,
Stenzl
A
,
Zdrojowy
R
,
Pluzanska
A
,
Szczylik
C
, et al
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
.
Nat Med
2012
;
18
:
1254
61
.
48.
Weide
B
,
Zelba
H
,
Derhovanessian
E
,
Pflugfelder
A
,
Eigentler
TK
,
Di Giacomo
AM
, et al
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis
.
J Clin Oncol
2012
;
30
:
1835
41
.
49.
Bijker
MS
,
van den Eeden
SJ
,
Franken
KL
,
Melief
CJ
,
van der Burg
SH
,
Offringa
R
. 
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
.
Eur J Immunol
2008
;
38
:
1033
42
.